Validated for Global Scale: DIAGNOS Passes Annual MDSAP Audit, Solidifying the Pathway to Approvals with Health Canada & FDA

Diagnos Inc. ("Diagnos" or the "Corporation") (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence ( AI ), announces the successful completion of the annual surveillance external quality compliance audit under the Medical Device Single Audit Program (MDSAP) performed in June of this year.

The audit confirmed full compliance across all operational and development processes, with no single non-conformities raised. This demonstrates Diagnos' strong commitment to quality, regulatory excellence, and continuous improvement.

Following this review, Intertek reissued the Company's certification with an updated scope reflecting Diagnos' Software-as-a-Service (SaaS) deployment model for its AI-assisted medical image-analysis platform. This evolution aligns the Company's quality framework with its expanding global strategy .

Yves-Stéphane Couture, COO of Diagnos, stated:

"This renewed certification demonstrates our readiness to scale our SaaS-based AI platform globally while maintaining the rigorous quality and compliance standards required by regulators. It's a strong signal to our partners and licensing bodies — Diagnos is accelerating the path to approvals with Health Canada, the FDA, and the SFDA . Our cloud deployment model allows us to deliver innovation faster, securely, and with measurable impact for healthcare providers."

"I would like to sincerely thank our Quality, Conformity, & Regulatory Affairs Specialist, Mr. Eric Boucher, and all Diagnos employees for their dedication throughout this process. Our clients expect our healthcare solutions to perform in compliance with the highest standards — and Diagnos continues to meet and exceed those expectations."

This successful audit strengthens Diagnos' position in ongoing regulatory submissions and supports its core mission which is centered on supporting Health Care Professionals (HCP) in early detection of critical health issues using Artificial Intelligence (AI) .

About MDSAP
MDSAP is a regulatory audit program of a medical device manufacturer's Quality management system. The program aims to reduce the number of audits a manufacturer undergoes by allowing a single annual audit to meet the regulatory needs of participating countries, which include assessing compliance with ISO 13485 and country-specific regulations.

About ISO 13485
ISO 13485 is the harmonized standard for Quality management system (QMS) in the medical device manufacturing industry. It outlines the requirements needed for organizations to establish a QMS that demonstrates the capability to consistently and safely deliver medical devices, and related services, as well as meeting customer and regulatory requirements.

About Diagnos
Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, Diagnos aims to provide more information to healthcare clinicians to enhance Diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.

Additional information is available at www.Diagnos.com and www.sedarplus.com .

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. Diagnos disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


For further information, please contact: Mr. André Larente, President Diagnos Inc. Tel: 450-678-8882 ext. 224 alarente@Diagnos.ca

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ADK:CC
The Conversation (0)
Contract Conversion with Major Australian Retail Bank

Contract Conversion with Major Australian Retail Bank

RocketBoots (ROC:AU) has announced Contract Conversion with Major Australian Retail BankDownload the PDF here. Keep Reading...
Syntheia Announces Shares for Debt Transaction

Syntheia Announces Shares for Debt Transaction

Syntheia Corp. (CSE: SYAI) ("Syntheia" or the "Company") (Syntheia.ai) is pleased to announce that it intends to settle an aggregate of $590,768.28 of indebtedness to certain creditors of the Company through the issuance of 4,923,069 common shares in the capital of the Company (the "Common... Keep Reading...
Contract Renewal & Additional Cash Inflows

Contract Renewal & Additional Cash Inflows

RocketBoots (ROC:AU) has announced Contract Renewal & Additional Cash InflowsDownload the PDF here. Keep Reading...
Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

RocketBoots (ROC:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
Q1 FY2026 Quarterly Activities and Cash Flow Report

Q1 FY2026 Quarterly Activities and Cash Flow Report

RemSense Technologies (REM:AU) has announced Q1 FY2026 Quarterly Activities and Cash Flow ReportDownload the PDF here. Keep Reading...
ExxonMobil Project Confirms REMs Top Tier Energy Position

ExxonMobil Project Confirms REMs Top Tier Energy Position

RemSense Technologies (REM:AU) has announced ExxonMobil Project Confirms REMs Top Tier Energy PositionDownload the PDF here. Keep Reading...

Latest Press Releases

Related News